Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stocks Ready To Explode!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Arbutus Biopharma (NASDAQ:ABUS) Stock Sees Selling Pressure At Higher Level

Arbutus Biopharma (NASDAQ:ABUS) dropped 9% last week. The company and Vaccitech Plc (NASDAQ: VACC) collaborated to study a combination of chronic hepatitis B virus treatment for patients receiving standard-of-care nucleotide reverse transcriptase inhibitor therapy.

The companies will assess the pharmacokinetics, immunogenicity, antiviral activity, and safety of the company’s AB-729 combination, followed by Vaccitech’s VTP-300 in the phase 2a study. The study will commence in 2H 2021, and Arbutus will manage the study with oversight from a joint development committee comprising Vaccitech and Arbutus.

The company and Antios Therapeutics Inc. also entered a clinical collaboration agreement to study a triple combination of the company’s novel GaINAc delivered RNAi therapy, AB-729, with ATI-2173, Antios Therapeutics’ active site polymerase inhibitor nucleotide, and Viread in treating chronic hepatitis B virus subjects. In addition, the companies will evaluate AB-729, ATI-2173, and Viread combination in the ongoing phase 2a ANTT201 clinical study run by Antios.  So, in the coming weeks, ABUS is a stock to watch.

Market Reaction:

On Friday, ABUS stock moved up slightly to close at $2.66 with more than 953k shares, compared to its average volume of 1.63 million shares. The stock has moved within a range of $2.5850 – 2.6800after opening the trade at $2.66. Over the past 52-week, the stock has been trading within a range of $2.2100 – 9.0200.

Published by Pete Matthews

Pete attended the University of Colorado and still calls the centennial state home. He chases trout in the summer and snowboards in the winter. He is fascinated with the markets and has a strong interest in nanocap stocks and crypto currency.

Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stocks Ready To Explode!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stocks Ready To Explode!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
*By submitting your information you agree to the terms of our Privacy Policy. You will receive the DRP Journal newsletter, and third party offers. You can unsubscribe anytime by selecting unsubscribe at the bottom of our emails.